REFERENCES
- Buchacz K, Brooks JT, Tong T, et al. Evaluation of hypophosphatemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected outpatients receiving highly active antiretroviral therapy. HIV Med. 2006;7:451–456.
- Badiou S, De Boever CM, Terrier N, et al. Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults? J Infect. 2006;52(5):335–358.
- Bech A, Bentum van P, Nabbe K, et al. Fibroblast growth factor 23 in hypophosphatemic HIV-positive adults on tenofovir [published online ahead of print March 30,2012]. HIV Med.
- Paccou J, Viget N, Legrout-Gerot I, et al. Bone loss in patients with HIV infection. Joint Bone Spine. 2009;76(6):637–641.
- Mc Comsey G. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. HIV/ AIDS. 2010;51:937–946.
- Madeddu G, Solines P, Celia GM, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. J Nucl Med Mol Imaging. 2004;48:39–48.
- Welz T, Childs K, Ibrahim F, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS. 2010:24;1923–1928.
- Mueller N, Fux C, Ledergerber B et al. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss patients. AIDS. 2010:24;1127–1134.
- Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57:773–780.
- Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infec-tion in adults: the first 4 years. AIDS. 2007;21:1273–1281.
- Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165–2174.
- Mallon PW. HIV and bone mineral density. Curr Opin Infect Dis. 2010;23(1)1–8.
- Grigsby IF, Pham L, Mansky LM, et al. Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochem Biophys Res Commun. 2010;394:48–53.
- Fux CA, Rauch A, Simcock M et al. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther 2008;13(8)1 077–1082
- Childs KE, Fishman SL, Constable C, et al. Short communication: inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses. 2010;26(8):855–859
- Ofotokun I, Weitzmann MN. HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture. Curr Opin Endocrinol Diabetes Obes. 2010;17(6):523–529.
- Briot K, Kolta S, Flandre P, et al. Prospective one-year bone loss in treatment-naïve HIV+ men and women on single or multiple drug HIV therapies. Bone. 2011;48(5)1133–1199.
- Hansen AB, Obel N, Nielsen H, et al. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Med. 2011;12(3):157–165.
- van Groningen L, Opdenoordt S, van Sorge A, et al. Cholecalciferol loading dose guideline for vitamin D-deficient adults. Eur J EndocrinoL 2010;162: 805–811.
- Bijvoet OL. Relation of plasma phosphate concentration to renal tubular reabsorption of phosphate. Clin Sci. 1969;37:23–36.
- Kemperman FA, Krediet RT, Arisz L. Formula-derived prediction of the glomerular filtration rate from plasma creatinine concentration. Nephron. 2002;91:547–558.